PHVS NASDAQ
Pharvaris N.V.
1W: +1.2%
1M: +2.0%
3M: +18.6%
YTD: +28.3%
1Y: +69.4%
3Y: +113.2%
5Y: +158.5%
$33.65
-0.33 (-0.96%)
Weekly Expected Move ±6.0%
$30
$32
$34
$36
$38
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.4B
52W Range19.12-36.6
Volume204,238
Avg Volume440,908
Beta-2.34
Dividend—
Analyst Ratings
Company Info
CEOBerndt Modig
Employees129
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-04
Websitepharvaris.com
Grafenauweg 8
Leiden, ZH 6300
NL
Leiden, ZH 6300
NL
31 71 203 6410
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Latest News
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) Price Target at $50.08
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Modig Berndt | S-Sale | 2,292 | $34.97 | 2026-07-13 |
| Lu Peng | F-InKind | 117 | $35.07 | 2026-07-12 |
| Lu Peng | F-InKind | 109 | $35.07 | 2026-07-11 |
| Schikan Johannes Ger | S-Sale | 30,712 | $35.49 | 2026-06-30 |
| Lesage Anne | M-Exempt | 24,900 | $8.05 | 2026-06-30 |